60 Degrees Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Efficiency
60 Degrees Pharmaceuticals, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has a cash flow conversion efficiency ratio of -0.883x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.23 Million) by net assets ($2.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
Cash flow conversion efficiency of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how 60 Degrees Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest 60 Degrees Pharmaceuticals, Inc. Common stock price today for real-time trading data and today's change.
60 Degrees Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Ratio Explained
60 Degrees Pharmaceuticals, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
60 Degrees Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 60 Degrees Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see 60 Degrees Pharmaceuticals, Inc. Common market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guard Therapeutics International AB
ST:GUARD
|
-1.630x |
|
Ankit Metal & Power Limited
NSE:ANKITMETAL
|
-0.018x |
|
CHRISTINA LAKE CANNABIS
F:CLB
|
0.102x |
|
GRI Bio Inc.
NASDAQ:GRI
|
-0.141x |
|
Korea SE Corp
KQ:101670
|
-0.024x |
|
De La Rue PLC
LSE:DLAR
|
2.021x |
|
Monsenso AS
CO:MONSO
|
-0.251x |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
-0.028x |
Annual Cash Flow Conversion Efficiency for 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. Review 60 Degrees Pharmaceuticals, Inc. Common (SXTP) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.38 Million | $-6.85 Million | -2.027x | -41.92% |
| 2024-12-31 | $3.96 Million | $-5.65 Million | -1.428x | -50.83% |
| 2023-12-31 | $4.80 Million | $-4.54 Million | -0.947x | -2363.88% |
| 2022-12-31 | $-24.15 Million | $-1.01 Million | 0.042x | +16.97% |
| 2021-12-31 | $-18.15 Million | $-649.11K | 0.036x | +286.20% |
| 2020-12-31 | $-18.07 Million | $-167.30K | 0.009x | -- |
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more